Neurimmune AG today announced the appointment of Alfred W. Sandrock, Jr., to its Board of Directors. Dr. Sandrock will work with Neurimmune’s Board and Executive Team to develop innovative drug candidates for the treatment of CNS and related protein aggregation diseases including Alzheimer’s disease.
Dr. Sandrock is recognized as an outstanding industry leader who brought numerous transformational therapies for the treatment of neurological diseases to patients. He spearheaded the development of Tysabri®, Tecfidera®, Spinraza®, Plegridy®, and most recently AduhelmTM. In his 23-year career at Biogen, Dr. Sandrock served in various functions including as an Executive Committee Member, Head of Research & Development and Chief Medical Officer.
“We are tremendously grateful that Al is joining Neurimmune. He will support our journey to develop transformative treatments for neurological conditions and related protein aggregation diseases. Al is an exceptional drug developer and a truly inspiring neuroscientist who pioneered the development and commercialization of more drugs than most of his peers. With his work, Al helped millions of patients with neurological disorders throughout the world to live a better life”, said Roger Nitsch, CEO & President of the Board of Neurimmune.
“Neurimmune has an impressive track record in developing therapeutic antibodies through the decoding of human immune responses occurring in healthy elderly subjects and patients with unusual slow decline of their disease,” said Dr. Sandrock. “The company’s dedication and commitment to develop next generation drug candidates against novel targets has always impressed me and I am very much looking forward to working together with the Neurimmune leadership team to develop treatments for patients suffering from neurological diseases”.
About Neurimmune
Neurimmune is a biopharmaceutical company translating human immune memory into transformative antibody therapeutics. Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, frontotemporal dementia, dementia with Lewy bodies and ATTR cardiomyopathy. Neurimmune discovered aducanumab, a human monoclonal antibody that removes amyloid beta from brains of patients with Alzheimer’s disease, and licensed it to Biogen. With its Reverse Translational MedicineTM technology, Neurimmune also discovered the anti-tau antibody BIIB076 for Alzheimer’s disease, the anti-miSOD1 antibody AP-101 for ALS and the anti-ATTR antibody NI006 for ATTR cardiomyopathy, programs being currently evaluated in clinical trials. Neurimmune has three additional antibody programs in preclinical development, and has recently expanded the spectrum of its treatment modalities by adding a small molecule program and programs involving vectorized expression of human antibody genes.
Contact for Media
Martin Meier-Pfister
+41 43 244 8140
media@neurimmune.com
